1. Principle
LC-MS (Liquid Chromatography–Mass Spectrometry):
Separates analytes in the liquid phase using HPLC and detects them with a mass spectrometer.
Suitable for non-volatile, thermally labile, polar, and high-molecular-weight compounds.
GC-MS (Gas Chromatography–Mass Spectrometry):
Separates analytes in the gaseous phase using gas chromatography, followed by mass spectrometric detection.
Best suited for volatile, thermally stable, and low-molecular-weight compounds.
2. Sample Requirements
LC-MS: No need for volatility; minimal derivatization required.
GC-MS: Requires analytes to be volatile, or chemically derivatized to achieve volatility.
3. Ionization Techniques
LC-MS: Soft ionization methods such as ESI (Electrospray Ionization) and APCI (Atmospheric Pressure Chemical Ionization); ideal for large biomolecules.
GC-MS: Hard ionization methods like EI (Electron Ionization) or CI (Chemical Ionization); produce extensive fragmentation, aiding structural elucidation.
4. Destructive Nature
Both LC-MS and GC-MS are destructive techniques since analytes are ionized and fragmented. The difference lies in the type of data generated, sensitivity, and applicability.
Applications in Pharmaceuticals
LC-MS:
Impurity profiling (including genotoxic impurities – GTIs)
Bioanalytical studies (PK/PD, metabolism)
Peptide/protein characterization
Residual solvents & polar, non-volatile impurities
Stability studies of non-volatile degradants
GC-MS:
Residual solvent analysis (ICH Q3C compliance)
Detection of volatile organic impurities
Extractables & leachables assessment
Identification of volatile degradation products
Profiling of volatile intermediates
Regulatory Perspective
Regulatory agencies (FDA, EMA, ICH):
Recommend LC-MS/MS for genotoxic impurities, nitrosamines, and metabolites.
Recognize GC-MS as the standard for residual solvents (ICH Q3C).
In practice: Residual Solvents → GC-MS | Genotoxic Impurities → LC-MS
Summary
LC-MS and GC-MS are complementary, not interchangeable. The choice depends on analyte properties, sensitivity requirements, and regulatory guidance. The pharmaceutical industry applies both techniques in parallel rather than relying on just one.